Control of Cerebral Blood Flow by KCa2 and KCa3

KCa2 ​​和 KCa3 对脑血流的控制

• 批准号: 8391870
• 负责人: ROBERT M BRYAN
• 金额: $ 23.48万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8391870
• 关键词: Agonist; Arteries; Biological Availability; Brain; Calcium-Activated Potassium Channel; Caliber; Cardiovascular system; Cell membrane; Cerebrovascular Circulation; Cerebrum; Clinical; Dilator; Endothelium; Erythrocytes; Flow-It; In Vitro; Ischemia; Laser-Doppler Flowmetry; Measures; Mediating; Nitric Oxide; P2Y2 receptor; Plasma; Potassium Channel; Prostaglandin-Endoperoxide Synthase; Prostaglandins I; Regulation; Relative (related person); Reperfusion Therapy; Rest; Role; Site; Stroke; Surface; Testing; Traumatic Brain Injury; Up-Regulation; Vascular resistance; arteriole; base; cerebral artery; cerebrovascular; clinical practice; clinically relevant; in vivo; inhibitor/antagonist; novel; therapeutic target

DESCRIPTION (provided by applicant): A novel endothelium-dependent dilator mechanism was identified in cerebral arteries and arterioles. This dilator mechanism has been called endothelium-derived hyperpolarizing factor (EDHF) or endothelium- dependent hyperpolarization (EDH).This mechanism, which does not involve nitric oxide (NO) or cyclooxygenase metabolites (i.e., prostacyclin), requires the activation of intermediate and/or small conductance calcium-activated K+ channels (IKCa and SKCa respectively) in cerebral vessels. Studies utilizing isolated cerebral arteries and arterioles provide circumstantial evidence that this dilator mechanism, involving IKCa and SKCa, may be as important as endothelium-derived NO in regulating cerebral blood flow (CBF). This idea is based on the key role of IKCa/SKCa in setting the resting diameter of cerebral arteries and arterioles, their contribution to endothelium-mediated dilations, and their relative importance compared to NO in penetrating arterioles, a site of major vascular resistance in the brain. In addition, dilations through IKCa/SKCa are enhanced following ischemia/reperfusion, traumatic brain injury, and other pathological states when NO bioavailability is diminished. Upregulation of IKCa/SKCa-mediated dilations may be an important protective strategy serving to compensate for decreased NO and ultimately limit reductions in CBF during pathological states. Although provocative, it is important to emphasize that studies to date involving IKCa/SKCa-mediated dilations have primarily used isolated cerebral vessels, which were removed from the brain and examined ex vivo in a vessel chamber. In order to fully understand the importance of IKCa and SKCa in controlling CBF, it is imperative that these studies are extended to the in vivo situation where arteries and arterioles function as a coordinated network in the cardiovascular system. Therefore, we propose to test the hypothesis that IKCa and/or SKCa channels regulate CBF in vivo. We propose to demonstrate that activation of IKCa and SKCa increase cerebral blood flow (Specific Aim 1). We will determine the contribution of IKCa and SKCa to resting CBF (Specific Aim 2). Finally, we will determine the contribution of IKCa and SKCa to increases in CBF elicited by ATP, an agonist released by red blood cells into the plasma (Specific Aim 3). Increases in CBF will be measured from the cortical surface using laser Doppler flowmetry following direct stimulation of IKCa and SKCa channels or indirectly through ATP, an agonist for endothelial P2Y2 receptors. For the specific aims, we will utilize selective pharmacological inhibitors to determine the relative contribution of IKCa and SKCa in controlling CBF. The need to conduct the proposed studies in vivo is amplified by the circumstantial evidence indicating an important role for IKCa/SKCa in regulating CBF. IKCa/SKCa channels could be of clinical relevance and a therapeutic target during pathological conditions where the bioavailability of NO is compromised. Furthermore, IKCa/SKCa channels could find their way into clinical practice in a manner similar to that of NO. PUBLIC HEALTH RELEVANCE: The control of cerebral blood flow is an important clinical consideration for a number of pathological states such as stroke and traumatic brain injury. Intermediate and small conductance potassium channels, which allow only K+ to pass across the cell membrane, appear to be an important mechanism for endothelial control of cerebral blood flow. The proposed studies will determine the role of these intermediate and small conductance potassium channels in the regulation of cerebral blood flow.

描述（由申请方提供）：在脑动脉和小动脉中发现了一种新的内皮依赖性扩张机制。这种扩张机制被称为内皮源性超极化因子（EDHF）或内皮依赖性超极化（EDH）。前列环素），需要激活脑血管中的中等和/或小电导钙激活的K+通道（分别为IKCa和SKCa）。利用离体脑动脉和小动脉的研究提供了间接证据，表明这种涉及IKCa和SKCa的扩张机制可能与内皮源性NO在调节脑血流量（CBF）中同样重要。这一想法是基于IKCa/SKCa在设定脑动脉和小动脉的静息直径中的关键作用，它们对内皮介导的扩张的贡献，以及它们与NO相比在穿透性小动脉中的相对重要性，穿透性小动脉是脑中主要血管阻力的部位。此外，当NO生物利用度降低时，缺血/再灌注、创伤性脑损伤和其他病理状态后，通过IKCa/SKCa的扩张增强。IKCa/SKCa介导的扩张的上调可能是一个重要的保护策略，用于补偿减少的NO，并最终限制在病理状态下CBF的减少。尽管具有挑衅性，但重要的是要强调，迄今为止涉及IKCa/SKCa介导的扩张的研究主要使用分离的脑血管，这些血管从大脑中取出并在血管室中进行离体检查。为了充分了解IKCa和SKCa在控制CBF中的重要性，这些研究必须扩展到体内情况，其中动脉和小动脉作为心血管系统中的协调网络发挥作用。因此，我们建议验证IKCa和/或SKCa通道在体内调节CBF的假设。我们建议证明IKCa和SKCa的激活增加脑血流量（具体目的1）。我们将确定IKCa和SKCa对静息CBF的贡献（具体目标2）。最后，我们将确定IKCa和SKCa对ATP引起的CBF增加的贡献，ATP是一种由红细胞释放到血浆中的激动剂（具体目标3）。直接刺激IKCa和SKCa通道后，或间接通过ATP（一种内皮P2 Y2受体激动剂），使用激光多普勒血流仪从皮质表面测量CBF的增加。为了达到特定的目的，我们将利用选择性药理学抑制剂来确定IKCa和SKCa在控制CBF中的相对贡献。间接证据表明IKCa/SKCa在调节CBF中具有重要作用，因此需要在体内进行拟议的研究。IKCa/SKCa通道可能具有临床意义，并且在NO的生物利用度受损的病理条件下是治疗靶点。此外，IKCa/SKCa通道可以以类似于NO的方式进入临床实践。 公共卫生相关性：脑血流量的控制是许多病理状态如中风和创伤性脑损伤的重要临床考虑。中电导和小电导钾通道仅允许K+穿过细胞膜，似乎是内皮控制脑血流的重要机制。拟议的研究将确定这些中电导和小电导钾通道在脑血流调节中的作用。